Biogen (NASDAQ:BIIB) Shares Acquired Rep. Maria Elvira Salazar

Representative Maria Elvira Salazar (Republican-Florida) recently bought shares of Biogen Inc. (NASDAQ:BIIB). In a filing disclosed on June 08th, the Representative disclosed that they had bought between $1,001 and $15,000 in Biogen stock on May 11th. The trade occurred in the Representative’s “UBS BROKERAGE ACCOUNT” account.

Representative Maria Elvira Salazar also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Brookfield Renewable Partners (NYSE:BEP) on 5/29/2026.
• Purchased $15,001 – $50,000 in shares of International Business Machines (NYSE:IBM) on 5/21/2026.
• Purchased $15,001 – $50,000 in shares of Datadog (NASDAQ:DDOG) on 5/19/2026.
• Purchased $1,001 – $15,000 in shares of Datadog (NASDAQ:DDOG) on 5/19/2026.
• Purchased $15,001 – $50,000 in shares of Qualcomm (NASDAQ:QCOM) on 5/13/2026.
• Purchased $1,001 – $15,000 in shares of Qualcomm (NASDAQ:QCOM) on 5/13/2026.
• Sold $1,001 – $15,000 in shares of Sherwin-Williams (NYSE:SHW) on 5/12/2026.
• Purchased $1,001 – $15,000 in shares of Biogen (NASDAQ:BIIB) on 5/12/2026.
• Purchased $50,001 – $100,000 in shares of Biogen (NASDAQ:BIIB) on 5/11/2026.
• Sold $1,001 – $15,000 in shares of Whirlpool (NYSE:WHR) on 5/11/2026.

Biogen Trading Down 2.4%

BIIB stock opened at $194.24 on Thursday. The company has a quick ratio of 2.41, a current ratio of 3.06 and a debt-to-equity ratio of 0.34. Biogen Inc. has a twelve month low of $121.05 and a twelve month high of $205.97. The stock has a market capitalization of $28.68 billion, a price-to-earnings ratio of 20.84 and a beta of 0.20. The firm’s fifty day simple moving average is $188.07 and its two-hundred day simple moving average is $184.03.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, beating analysts’ consensus estimates of $2.95 by $0.62. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The business had revenue of $2.48 billion for the quarter, compared to analysts’ expectations of $2.29 billion. During the same quarter in the previous year, the business posted $3.02 earnings per share. The business’s revenue was up 1.9% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, analysts anticipate that Biogen Inc. will post 14.18 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. HC Wainwright restated a “buy” rating on shares of Biogen in a report on Thursday, May 14th. Piper Sandler restated an “overweight” rating and issued a $225.00 price target (up from $214.00) on shares of Biogen in a report on Friday, May 15th. Morgan Stanley upped their price target on shares of Biogen from $200.00 to $206.00 and gave the stock an “equal weight” rating in a report on Thursday, April 30th. The Goldman Sachs Group upped their price target on shares of Biogen from $231.00 to $238.00 and gave the stock a “buy” rating in a report on Friday, April 24th. Finally, Argus upgraded shares of Biogen to a “hold” rating in a report on Thursday, April 9th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Biogen presently has a consensus rating of “Moderate Buy” and an average target price of $217.26.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BIIB. Vanguard Group Inc. raised its stake in shares of Biogen by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 17,447,092 shares of the biotechnology company’s stock worth $3,070,514,000 after acquiring an additional 157,857 shares in the last quarter. Geode Capital Management LLC grew its stake in Biogen by 3.2% in the 4th quarter. Geode Capital Management LLC now owns 4,199,399 shares of the biotechnology company’s stock valued at $736,435,000 after acquiring an additional 130,618 shares during the period. Norges Bank acquired a new stake in Biogen during the 4th quarter worth $464,408,000. Invesco Ltd. raised its holdings in shares of Biogen by 4.2% during the 3rd quarter. Invesco Ltd. now owns 2,418,127 shares of the biotechnology company’s stock worth $338,731,000 after acquiring an additional 98,001 shares during the period. Finally, Morgan Stanley raised its holdings in shares of Biogen by 3.3% during the 4th quarter. Morgan Stanley now owns 2,325,013 shares of the biotechnology company’s stock worth $409,180,000 after acquiring an additional 73,478 shares during the period. 87.93% of the stock is currently owned by institutional investors.

About Representative Salazar

Maria Elvira Salazar (Republican Party) is a member of the U.S. House, representing Florida’s 27th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.

Salazar (Republican Party) ran for re-election to the U.S. House to represent Florida’s 27th Congressional District. She won in the general election on November 5, 2024.

Maria Elvira Salazar was born in Miami, Florida, and lives in Coral Gables, Florida. Salazar earned an undergraduate degree from the University of Miami in 1983 and a graduate degree from Harvard University in 1995. Her career experience includes working as a television journalist, reporter, and news anchor.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.